IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
Zhou, Caicun; Wu, Yi Long; Liu, Xiaoqing; Wang, Changli; Chen, Gongyan; Feng, Ji Feng; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Cheng-ping; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu
刊名JOURNAL OF CLINICAL ONCOLOGY
2012-05-20
suppl.S期:15
收录类别SCI ; ISTP
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
语种英语
WOS记录号WOS:000318009804317
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66429
专题北京大学临床肿瘤学院
作者单位1.Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China
2.Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
3.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
4.Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
5.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
6.Acad Mil Med Sci, Ctr Canc, Hosp 307, Beijing, Peoples R China
7.Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
8.Capital Med Univ, Bejiing Chest Hosp, Beijing, Peoples R China
9.Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
10.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
11.Shanghai Jiao Tong Univ, Renjin Hosp, Shanghai 200030, Peoples R China
12.Capital Med Univ, Beijing Lung Canc Ctr, Beijing, Peoples R China
13.Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China
14.Cent S Univ, Xiang Ya Hosp, Changsha, Hunan, Peoples R China
15.Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
16.Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China
17.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
18.Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
推荐引用方式
GB/T 7714
Zhou, Caicun,Wu, Yi Long,Liu, Xiaoqing,et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)[J]. JOURNAL OF CLINICAL ONCOLOGY,2012,suppl.S(15).
APA Zhou, Caicun.,Wu, Yi Long.,Liu, Xiaoqing.,Wang, Changli.,Chen, Gongyan.,...&Xiu, Qingyu.(2012).Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY,suppl.S(15).
MLA Zhou, Caicun,et al."Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)".JOURNAL OF CLINICAL ONCOLOGY suppl.S.15(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhou, Caicun]的文章
[Wu, Yi Long]的文章
[Liu, Xiaoqing]的文章
百度学术
百度学术中相似的文章
[Zhou, Caicun]的文章
[Wu, Yi Long]的文章
[Liu, Xiaoqing]的文章
必应学术
必应学术中相似的文章
[Zhou, Caicun]的文章
[Wu, Yi Long]的文章
[Liu, Xiaoqing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。